CoChat
Sign Up
Cited by 235Advanced Breast Cancer TherapiesBreast Cancer Treatment StudiesPARP inhibition in cancer therapy

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.

Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)

Open access
Gnant, Michael, Dueck, Amylou C., Frantal, Sophie, Martin, Miguel, Burstein, Hal J., Greil, Richard, Fox, Peter, Wolff, Antonio C., Chan, Arlene, Winer, Eric P., Pfeiler, Georg, Miller, Kathy D., Colleoni, Marco, Suga, Jennifer M., Rubovsky, Gabor, Bliss, Judith M., Mayer, Ingrid A., Singer, Christian F., Nowecki, Zbigniew, Hahn, Olwen, Thomson, Jacqui, Wolmark, Norman, Amillano, Kepa, Rugo, Hope S., Steger, Guenther G., Hernando Fernández de Aránguiz, Blanca, Haddad, Tufia C., Perelló, Antonia, Bellet, Meritxell, Fohler, Hannes, Metzger Filho, Otto, Jallitsch-Halper, Anita, Solomon, Kadine, Schurmans, Céline, Theall, Kathy P., Lu, Dongrui R., Tenner, Kathleen, Fesl, Christian, DeMichele, Angela, Mayer, Erica L., on behalf of the PALLAS groups and investigators·2022·Journal of Clinical Oncology
DOI 10.1200/jco.21.02554PMC PMC10476784
Open this paper in CoChat — free accountOpen PDF

Abstract

PURPOSE: Palbociclib is a cyclin-dependent kinase 4 and 6 inhibitor approved for advanced breast cancer. In the adjuvant setting, the potential value of adding palbociclib to endocrine therapy for hormone receptor–positive breast cancer has not been confirmed. PATIENTS AND METHODS: In the prospective, randomized, phase III PALLAS trial, patients with hormone receptor–positive, human epidermal growth factor receptor 2–negative early breast cancer were randomly assigned to receive 2 years of palbociclib (125 mg orally once daily, days 1-21 of a 28-day cycle) with adjuvant endocrine therapy or adjuvant endocrine therapy alone (for at least 5 years). The primary end point of the study was invasive disease-free survival (iDFS); secondary end points were invasive breast cancer–free survival, distant recurrence-free survival, locoregional cancer-free survival, and overall survival. RESULTS: Among 5,796 patients enrolled at 406 centers in 21 countries worldwide over 3 years, 5,761 were included in the intention-to-treat population. At the final protocol-defined analysis, at a median follow-up of 31 months, iDFS events occurred in 253 of 2,884 (8.8%) patients who received palbociclib plus endocrine therapy and in 263 of 2,877 (9.1%) patients who received endocrine therapy alone, with similar results between the two treatment groups (iDFS at 4 years: 84.2% v 84.5%; hazard ratio, 0.96; CI, 0.81 to 1.14; P = .65). No significant differences were observed for secondary time-to-event end points, and subgroup analyses did not show any differences by subgroup. There were no new safety signals for palbociclib in this trial. CONCLUSION: At this final analysis of the PALLAS trial, the addition of adjuvant palbociclib to standard endocrine therapy did not improve outcomes over endocrine therapy alone in patients with early hormone receptor–positive breast cancer.

Overview

Integrity signals

Registry

Crossref · 10.1200/jco.21.02554

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 46 references

Cited by

Sorted by citations

See all 235

Related

Metadata

Authors
Gnant, M., Dueck, A. C., Frantal, S., Martin, M., Burstein, H. J., Greil, R., Fox, P., Wolff, A. C., Chan, A., Winer, E. P., Pfeiler, G., Miller, K. D., Colleoni, M., Suga, J. M., Rubovsky, G., Bliss, J. M., Mayer, I. A., Singer, C. F., Nowecki, Z., Hahn, O., Thomson, J., Wolmark, N., Amillano, K., Rugo, H. S., Steger, G. G., Hernando Fernández de Aránguiz, B., Haddad, T. C., Perelló, A., Bellet, M., Fohler, H., Metzger Filho, O., Jallitsch-Halper, A., Solomon, K., Schurmans, C., Theall, K. P., Lu, D. R., Tenner, K., Fesl, C., DeMichele, A., Mayer, E. L., & on behalf of the PALLAS groups and investigators
Affiliations
  • Comprehensive Cancer Center Vienna (AT)
  • Mayo Clinic (US)
  • Austrian Breast & Colorectal Cancer Study Group (AT)
  • Hospital General Universitario Gregorio Marañón, Madrid, Spain
  • Dana-Farber Cancer Institute (US)
  • Paracelsus Medical University (AT)
  • Government of New South Wales (AU)
  • Johns Hopkins University (US)
  • Curtin University (AU)
  • Indiana University Health (US)
  • European Institute of Oncology (IT)
  • Kaiser Permanente Vallejo Medical Center (US)
  • National Institute of Oncology, Budapest, Hungary
  • Institute of Cancer Research (GB)
  • Vanderbilt University Medical Center (US)
  • The Maria Sklodowska-Curie National Research Institute of Oncology (PL)
  • University of Chicago (US)
  • Peninsula Health (AU)
  • University of Pittsburgh (US)
  • Hospital Universitari Sant Joan de Reus (ES)
  • University of California, San Francisco (US)
  • GEICAM Spanish Breast Cancer Group, Madrid, Spain
  • Hospital Universitario Son Espases (ES)
  • Vall d'Hebron Institute of Oncology (ES)
  • Alliance Foundation Trials (US)
  • BIG, Brussels, Belgium
  • Pfizer (United States) (US)
  • University of Pennsylvania (US)
  • GEICAM – Spanish Breast Cancer Group (ES)
ORCID
Venue
Journal of Clinical Oncology
Publisher
American Society of Clinical Oncology (ASCO)
Published
2022-01-20
Volume
40
Issue
3
Pages
282-293
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
DOI
10.1200/jco.21.02554
PMC
PMC10476784
OpenAlex
W4200066800
Cited by
235
References
46
Citations by year
2026: 26 · 2025: 70 · 2024: 56 · 2023: 51 · 2022: 32
FWCI
22.57
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Oncology (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • IUScholarWorks (Indiana University) (submittedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
  • Pfizer
  • Cancer Research UK (25351)
  • National Institute for Health and Care Research (NIHR202432)
  • National Cancer Institute (U10CA180868, R01CA214893)
Topics
  • Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
  • Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
Keywords
palbociclib, early breast cancer, hormone receptor-positive breast cancer, HER2-negative breast cancer, adjuvant therapy, endocrine therapy, invasive disease-free survival, PALLAS trial
MeSH terms
Progression-Free Survival, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Female, Humans, Mastectomy, Middle Aged, Neoplasm Staging, Piperazines, Prospective Studies, Pyridines, Time Factors, Chemotherapy, Adjuvant, Disease Progression, Disease-Free Survival, Antineoplastic Agents, Hormonal, Neoadjuvant Therapy, Protein Kinase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review